Oryon Cell treatments is a clinical-stage biotechnology business exploring autologous cell treatments for neurodegenerative illnesses.
Oryon Cell Therapies has raised $21.0M in total funding. The most recent round was Series A. The last funding was announced in March 2026.
Oryon Cell Therapies's investors include Neuro.VC, Byers Capital.
Oryon Cell Therapies is headquartered in Belmont, United States.
Oryon Cell treatments is a clinical-stage biotechnology business exploring autologous cell treatments for neurodegenerative illnesses.
Oryon Cell Therapies is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Oryon Cell Therapies — Funding & Investors." VCBacked, March 23, 2026, https://www.vcbacked.co/company/oryon-cell-therapies. Accessed August 14, 2026.
VCBacked. (2026). Oryon Cell Therapies — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/oryon-cell-therapies
{{cite web |title=Oryon Cell Therapies — Funding & Investors |url=https://www.vcbacked.co/company/oryon-cell-therapies |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated